Coripharma Is A European Generic Pharmaceutical Company Based In Hafnarfja Ra Uricelandfounded In 2018 By Former Actavis Employees And Investorsthecompany Has A Strong Background In Thepharmaceutical Industrystemming From Theacquisition Of Actavis Ehfcoripharma Specializes In Developing Its Own Pharmaceutical Products And Offers Out Licensing Opportunities To Other Generic Pharmaceutical Companiesthecompany Also Provides Contract Manufacturing Servicesutilizing Its Established Facilities And Expertiseto Producepharmaceuticals For Clientscoripharma Has Successfully Launched Fiveof Its Own Developed Productsincluding Ruxolitinibwhich Is Used To Treat Primary Myelofibrosiswith A Reported Revenueof Approximately $17 7 Million And Over 200 Employees As Of 2024Coripharma Continues To Grow And Expand Its Presencein Thegeneric Pharmaceutical Market
Germany
